Plasma Fractionation Market Size, by Product {Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin}, Application (Immunology, Hematology, Critical Care, Rheumatology, Neurology), End-user (Hospitals, Clinical Research Lab, Academic Institutes) - Growth Trends, Regional Share, Competitive Intelligence, Forecast Report 2025-2037

Plasma Fractionation Sector: Growth Drivers and Challenges

Growth Drivers

• Proliferation in the Number of Chronic Diseases –There have been growing cases of chronic disease, which has increased the demand for its treatments. Among various treatments, plasma therapy is the most extensively used treatment. Hence, the plasma fractionation market is expected to grow further over the forecast period. For instance, the most common and expensive medical illnesses in the US are chronic diseases. About 133 million Americans, or roughly 45% of the population, have at least one chronic illness, and the number is rising.
• Growing Geriatric Population – Old people have a weakened immune system and are prone to both chronic and acute diseases. Thus, for effective diagnostic and treatment procedures plasma fractionation has become imperative which is projected to create a positive outlook by the end of the forecast period. According to the World Health Organization figures, by 2030, one in every six persons on the planet would be 60 or older.
• Increased Investment by Major Players in Effective Treatment – For instance, CSL Behring & Takeda Pharmaceutical Company Ltd. collaborated with Biotest, BPL, LFB, and Octapharma to develop an effective plasma-derived drug for the treatment of COVID-19.
• Increasing Autoimmune Diseases - According to current estimates, the number of autoimmune disease cases worldwide is increasing between 3% to approximately 10% yearly.
• Unhealthy Lifestyle Involving Consumption of Alcohol, Tobacco, and Fast Food – The recent shift of the population towards an unhealthy lifestyle has made the human body weak and with a low resistance to fight diseases and illnesses. As a result, for the diagnosing and treatment of these disorders, the demand for products from plasma fractionation is forecasted to increase in the upcoming years. According to the Centers for Disease Control and Prevention, 25.1% of adults aged 18 and over in the world are reported to have at least one day of heavy drinking (five or more drinks for males and four or more drinks for women) during the previous year.

Challenges

• High-Cost Related to Plasma Therapy - Plasma therapy is usually an expensive one, as it proves to be a lifesaver in severe cases where the patient has suffered trauma, burn, or severe kind of liver disorder and is in dire need of plasma. The recent scenario of the pandemic has also seen the great importance of plasma therapy such as convalescent plasma therapy, in the treatment of severe patients with Covid-19. For instance, it was observed in a clinical study that convalescent plasma was capable of substantially lower down the 28-day mortality and mechanical ventilation time of severe or critical COVID-19 patients. However, when plasma therapy is not given on time, usually when the symptoms are moderate, the cost is expected to increase, hence hindering the growth of the plasma fractionation market.
• Increasing the Use of Recombinant Alternatives
• Restricted Medical Reimbursement Policies